Crescent Biopharma, Inc.

CBIO ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Assets
Cash & Equivalents $213.2M $34.8M $41.8M $47.9M $90.3M $137.0M $158.2M $209.9M
Accounts Receivable $18.0M $0 — — — — — —
Inventory — — — — — — — —
Total Current Assets $236.7M $34.8M $43.8M $50.7M $90.8M $138.3M $162.5M $212.3M
Property, Plant & Equipment $846.0K $0 — $242.4K $368.8K $620.7K $822.9K $957.2K
Goodwill — — — — — — — —
Intangible Assets (Excl. Goodwill) — — — — — — — —
Total Assets $240.3M $35.6M $45.3M $51.8M $94.3M $142.8M $168.0M $214.8M
Liabilities
Accounts Payable — $329.3K $868.1K $970.2K $2.1M $2.1M $1.4M $2.7M
Total Current Liabilities $36.1M $9.6M $6.8M $8.9M $11.8M $12.4M $11.0M $8.8M
Long-Term Debt — — — — — — — —
Total Liabilities $37.3M $47.1M $6.9M $8.9M $12.7M $14.6M $13.8M $9.4M
Stockholders' Equity
Retained Earnings $-171.8M $-17.9M $-456.5M $-419.6M $-372.9M $-309.5M $-258.4M $-200.6M
Total Stockholders' Equity $203.0M $-15.5M $38.4M $42.9M $81.6M $128.2M $154.2M $205.5M
← Newer Page 1 of 2 Older →